KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424

[2] Ferlay J(2015)Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010 JAMA Surg. 150 17-22

[3] Soerjomataram I(2014)Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer Anticancer Res. 34 2061-2068

[4] Siegel RL(2016)Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait” Int J Colorectal Dis. 31 413-419

[5] Torre LA(2015)Rectal cancer: An evidence-based update for primary care providers World J Gastroenterol. 21 7659-7671

[6] Jemal A(2010)A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist. 15 699-731

[7] Bailey CE(2011)Predictive and prognostic markers in colorectal cancer Curr Oncol Rep. 13 206-215

[8] Hu CY(2015)Analysis of K-ras codon 12 and TP53 mutations in patients with advanced colorectal carcinoma S Afr Med J. 105 670-674

[9] You YN(2010)Molecular markers in the treatment of metastatic colorectal cancer Cancer J. 16 262-272

[10] Bednarski BK(2019)Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status J Gastrointest Oncol. 10 886-895

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424

[2] Ferlay J(2015)Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010 JAMA Surg. 150 17-22

[3] Soerjomataram I(2014)Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer Anticancer Res. 34 2061-2068

[4] Siegel RL(2016)Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait” Int J Colorectal Dis. 31 413-419

[5] Torre LA(2015)Rectal cancer: An evidence-based update for primary care providers World J Gastroenterol. 21 7659-7671

[6] Jemal A(2010)A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy Oncologist. 15 699-731

[7] Bailey CE(2011)Predictive and prognostic markers in colorectal cancer Curr Oncol Rep. 13 206-215

[8] Hu CY(2015)Analysis of K-ras codon 12 and TP53 mutations in patients with advanced colorectal carcinoma S Afr Med J. 105 670-674

[9] You YN(2010)Molecular markers in the treatment of metastatic colorectal cancer Cancer J. 16 262-272

[10] Bednarski BK(2019)Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status J Gastrointest Oncol. 10 886-895